<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00826878</url>
  </required_header>
  <id_info>
    <org_study_id>AV-951-08-105</org_study_id>
    <nct_id>NCT00826878</nct_id>
  </id_info>
  <brief_title>An Open-Label Study of QD Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer (NSCLC)</brief_title>
  <official_title>A Phase 1b/2a Open-Label Study to Evaluate the Safety and Activity of Once Daily Oral Administration of Tivozanib (AV-951) in Subjects With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AVEO Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AVEO Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a standard Phase 1b and 2a, multi-center, study design that will examine the safety,
      tolerability, and maximum tolerated dose of tivozanib (AV-951) with this dosing schedule, as
      well as overall response rate of tivozanib (AV-951) administration in NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 2a portion of the study was not conducted
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ph1b: To determine the safety, tolerability, and MTD of tivozanib (AV-951) administered orally QD in subjects with NSCLC</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph2a: To determine the ORR of tivozanib (AV-951) administered orally once daily in subjects with NSCLC with no prior anti-angiogenic therapy</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ph1b: To evaluate the PK of tivozanib (AV-951) administered orally QD</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph1b: To evaluate the preliminary antineoplastic activity of tivozanib (AV-951) administered orally QD</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph2a: To determine the duration of complete and partial responses and time to disease progression (TTP) for subjects treated with tivozanib (AV-951)</measure>
    <time_frame>8 weeks (2 cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph2a: To determine the safety and tolerability of tivozanib (AV-951) administered orally once a day</measure>
    <time_frame>4 weeks (1 cycle)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Tivozanib (AV-951)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tivozanib (AV-951)</intervention_name>
    <description>Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.
Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated.</description>
    <arm_group_label>Tivozanib (AV-951)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or older, of either sex and of any race.

          2. Histologically or cytologically confirmed NSCL.

          3. Stage IIIB (with malignant pleural effusion) or stage IV or recurrent disease.

          4. Subjects that have recurred or progressed following standard therapy or failed
             standard therapy; or subjects that are not candidates for or unwilling to undergo
             standard therapy.

          5. Disease that is currently not amenable to curative surgical intervention, due to
             either non-resectability of the tumor or medical contraindications.

          6. Prior VEGF directed therapy

          7. Prior chemotherapy

          8. At least 4 weeks since prior immunotherapy (eg, IL-2, IFN, etc.) or biological therapy
             (eg, MABs) prior to the first dose of study drug.

          9. At least 1 week since prior treatment with warfarin, acenocoumarol, fenprocoumon, or
             similar agents.

         10. At least 4 weeks since prior systemic hormonal therapy.

         11. At least 2 weeks since prior use of herbal preparations/supplements.

         12. At least 2 weeks since prior treatment with CYP3A4 inducers or inhibitors.

         13. At least 2 weeks since prior radiotherapy to ≤25% of bone marrow, or at least 4 weeks
             since prior radiotherapy to &gt; 25% of bone marrow.

         14. Measurable or evaluable disease; subjects enrolled in the Phase 2a study must have
             measurable disease by RECIST criteria.

         15. ECOG performance 0-1 and life expectancy ≥ 3 months.

         16. Ability to give written informed consent.

        Exclusion Criteria:

          1. Subjects with central lung lesions involving major blood vessels.

          2. Primary CNS malignancies or symptomatic CNS metastases; subjects with previously
             treated brain metastasis will be allowed if the brain metastasis have been stable
             without steroid treatment for at least 3 months following prior treatment
             (radiotherapy or surgery).

          3. Hematologic malignancies (including leukemia in any form, lymphoma, and multiple
             myeloma).

          4. Hematologic abnormalities:

          5. Serum chemistry abnormalities:

          6. Significant cardiovascular disease

          7. Subjects with delayed healing of wounds, active gastric ulcers, or unhealed bone
             fractures.

          8. Serious/active infection or infection requiring parenteral antibiotics.

          9. Inadequate recovery from any prior surgical procedure or major surgical procedure
             within 6 weeks prior to administration of first dose of study drug.

         10. Inability to comply with protocol requirements.

         11. History of ≥ Grade 2 hemoptysis within 6 months prior to administration of first dose
             of study drug; ongoing bleeding (hemoptysis, hematemesis, hematochezia or melena) or
             history of clinically significant bleeding within 6 months prior to administration of
             first dose of study drug.

         12. Cerebrovascular accident within 12 months prior to administration of first dose of
             study drug, or peripheral vascular disease with claudication on walking less than 1
             block.

         13. Deep venous thrombosis or pulmonary embolus within 6 months prior to administration of
             first dose of study drug.

         14. Subjects with a &quot;currently active&quot; second primary malignancy other than non-melanoma
             skin cancers or nonmetastatic prostate cancer. Subjects are not considered to have a
             &quot;currently active&quot; malignancy if they have completed anti-cancer therapy and have been
             disease free for &gt;2 years.

         15. If female, pregnant or lactating.

         16. No childbearing potential or the use of effective contraception by all fertile male
             and female subjects during the study and for 30 days after the last dose of study
             drug. All subjects must agree to use a highly effective method of contraception
             (including their partner).

         17. Known concomitant genetic or acquired immune suppression disease such as HIV.

         18. Inadequate recovery from prior antineoplastic therapy.

         19. Life-threatening illness or organ system dysfunction compromising safety evaluation.

         20. Psychiatric disorder, altered mental status precluding informed consent or necessary
             testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaroslaw Jac, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>AVEO Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jimmy Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chao Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naiyer Rizvi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>June 27, 2012</last_update_submitted>
  <last_update_submitted_qc>June 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tivozanib</keyword>
  <keyword>AV-951</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

